European cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.0% during the forecast period. Increasing launches of monoclonal antibodies biosimilars is offering an opportunity for market growth. For instance, in April 2020, Pfizer Inc. declared the European Commission approval of RUXIENCE (rituximab). It is a monoclonal antibody and biosimilar to MabThera (rituximab), which aims to treat granulomatosis with polyangiitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, rheumatoid arthritis, microscopic polyangiitis, and pemphigus vulgaris. The biosimilars’ approval including RUXIENCE is an essential development to treat certain cancers and autoimmune conditions. It offers effectiveness to improve access to treatment access while minimizing healthcare costs.
To Request a Sample of our Report on European cancer monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/european-cancer-monoclonal-antibodies-market
Additionally, in February 2018, Celltrion Healthcare declared the European Commission approval of Herzuma (trastuzumab biosimilar, CT-P6). This is intended for all indications offered by reference trastuzumab in the EU. It is the third Celltrion Healthcare product that was approved in the EU and established on the company’s increasing biosimilar portfolio. This has led the company to market Herzuma in all 28 EU member states and the European Economic Area to treat patients suffering from metastatic breast cancer, early breast cancer, or metastatic gastric cancer. These launches of biosimilars represent the European Commission’s focus towards increasing access to cancer treatment in the region, which in turn, will accelerate the market growth.
Scope of the European Cancer Monoclonal Antibodies Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Countries Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
- Competitive Landscape- AstraZeneca plc, Pfizer Inc., F- Hoffman La-Roche AG, Novartis AG, and Mylan N.V.
Recent Strategic Initiatives in the European Cancer Monoclonal Antibodies Market
- In June 2020, Sanofi S.A. declared the European Commission approval of Sarclisa (isatuximab) along with dexamethasone (pom-dex) and pomalidomide to treat adults suffering from relapsed and refractory multiple myeloma. It is a monoclonal antibody that attaches to a particular epitope on the CD38 receptor of MM cells.
- In January 2020, Roche declared that the European Commission has permitted conditional marketing authorization for Polivy (polatuzumab vedotin), along with bendamustine plus MabThera (rituximab) (BR), to treat adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant.
(Get 15% Discount on Buying this Report)
A full Report of European cancer monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/european-cancer-monoclonal-antibodies-market
Key questions addressed by the report
- What is the market growth rate?
- Which country/segment dominates the market in the base year?
- Which country/segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
Ø Recovery Timeline
Ø Deviation from the pre-COVID forecast
Ø Most affected country/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
European Cancer Monoclonal Antibodies Market-Segmentation
By Type
- Naked
- Conjugated
- Others (Bispecific)
By Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
